Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective

被引：1

作者：

Elkeraie, Ahmed Fathi ^{[1
]}

Al-Ghamdi, Saeed ^{[2
]}

Abu-Alfa, Ali K. ^{[3
]}

Alotaibi, Torki ^{[4
]}

Alsaedi, Ali Jasim ^{[5
]}

Alsuwaida, Abdulkareem ^{[6
]}

Arici, Mustafa ^{[7
]}

Ecder, Tevfik ^{[1
,8
]}

Ghnaimat, Mohammad ^{[9
]}

Hafez, Mohamed Hany ^{[10
]}

Hassan, Mohamed H. ^{[11
]}

Sqalli, Tarik ^{[12
]}

机构：

[1] Alexandria Univ, Dept Internal Med & Nephrol, Alexandria, Egypt

[2] King Abdulaziz Univ, Coll Med, Dept Med, Jeddah, Saudi Arabia

[3] Amer Univ Beirut, Dept Internal Med, Div Nephrol & Hypertens, Beirut, Lebanon

[4] Sabah Hlth Reg, Hamed Al Essa Organ Transplant Ctr, Transplant Nephrol, Kuwait, Kuwait

[5] Univ Baghdad, Coll Med, Nephrol & Transplantat Ctr, Dept Nephrol, Baghdad, Iraq

[6] King Saud Univ, Dept Med, Riyadh, Saudi Arabia

[7] Hacettepe Univ, Fac Med, Dept Nephrol, Ankara, Turkiye

[8] Istinye Univ, Dept Med, Div Nephrol, Sch Med, Istanbul, Turkiye

[9] Specialty Hosp, Dept Nephrol, Jaber Ibn Hayyan St Shmeisani, Amman, Jordan

[10] Cairo Univ, Dept Nephrol & Med, Cairo, Egypt

[11] Dept Med, Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates

[12] Moroccan Soc Nephrol, Dept Nephrol, Casablanca, Morocco

来源：

INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE | 2024年 / 17卷

关键词：

chronic kidney disease; nephrology referral; screening; sodium-glucose cotransporter-2 inhibitors; CARDIOVASCULAR OUTCOMES; SGLT2; INHIBITORS; PROGRESSION; ALBUMINURIA; HEALTH; RISK; DAPAGLIFLOZIN; HYPERTENSION; ELECTROLYTE; PREVALENCE;

D O I：

10.2147/IJNRD.S430532

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Chronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter -2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD.

引用

页码：1 / 16

页数：16

共 50 条

[31] Perioperative management of sodium-glucose cotransporter-2 inhibitors: importance of a nuanced approach
Nanjappa, N.
Jesudason, D.
Thiruvenkatarajan, V.
Meyer, E. J.
ANAESTHESIA AND INTENSIVE CARE, 2018, 46 (04) : 424 - 425
[32] Role of sodium-glucose cotransporter-2 inhibitors in risk of chronic kidney disease among patients with type 2 diabetes mellitus
Tung-Sheng Chen
Teng-Shun Yu
Cheng-Li Lin
Chung Y. Hsu
Wei-Syun Hu
Journal of Nephrology, 2023, 36 : 713 - 718
[33] The impact of sodium-glucose cotransporter-2 inhibitors on the outcome of patients with colorectal adenocarcinoma
Chiang, Cho Han
Chiang, Cho Hung
Hsia, Yuanping
See, Xin Ya
Wang, Shih-Syuan
Chen, Yuan-Jen
Peng, Chun-Yu
Horng, Chuan-Sheng
Wong, Kit Yee
Jaroenlapnopparat, Aunchalee
Liu, Weitao
Chiang, Cho Hsien
Shiah, Her-Shyong
Neilan, Tomas G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure
Talha, Khawaja M.
Butler, Javed
Greene, Stephen J.
Aggarwal, Rahul
Anker, Stefan D.
Claggett, Brian L.
Docherty, Kieran F.
Solomon, Scott D.
McMurray, John J. V.
Januzzi, James L.
Vaduganathan, Muthiah
Fonarow, Gregg C.
EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (07) : 999 - 1009
[35] The Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Atrial Electromechanical Conduction Time
Celik, Enes
Kerkutluoglu, Murat
Sahin, Murat
Aksu, Ekrem
Balcioglu, Akif Serhat
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2024, 52 (04): : 237 - 243
[36] Role of sodium-glucose cotransporter-2 inhibitors in risk of chronic kidney disease among patients with type 2 diabetes mellitus
Chen, Tung-Sheng
Yu, Teng-Shun
Lin, Cheng-Li
Hsu, Chung Y.
Hu, Wei-Syun
JOURNAL OF NEPHROLOGY, 2023, 36 (03) : 713 - 718
[37] Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease
El Din, Usama Abdel Azim Sharaf
Salem, Mona Mansour
Abdulazim, Dina Ossama
NEFROLOGIA, 2022, 42 (04): : 390 - 403
[38] Sodium-glucose cotransporter 2 inhibitors for chronic kidney disease: Why, when and when not
Javaid, Muhammad M.
Frederick, Rachel
Itrat, Sheema
Ekladious, Adel
AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2024, 53 (12)
[39] Sodium-Glucose Cotransporter-2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
Porcari, Aldostefano
Cappelli, Francesco
Nitsche, Christian
Tomasoni, Daniela
Sinigiani, Giulio
Longhi, Simone
Bordignon, Luca
Masri, Ahmad
Serenelli, Matteo
Urey, Marcus A.
Musumeci, Beatrice
Cipriani, Alberto
Canepa, Marco
Eslam, Roza Badr
Kronberger, Christina
Chimenti, Cristina
Zampieri, Mattia
Allegro, Valentina
Razvi, Yousuf
Patel, Rishi
Ioannou, Adam
Rauf, Muhammad U.
Petrie, Aviva
Whelan, Carol
Emdin, Michele
Metra, Marco
Merlo, Marco
Sinagra, Gianfranco
Hawkins, Philip
Solomon, Scott
Gillmore, Julian
Fontana, Marianna
CIRCULATION, 2023, 148 (25) : E303 - E303
[40] Sodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?
Imbrici, Paola
d'Orsi, Giuseppe
Carella, Massimo
Nicolotti, Orazio
De Luca, Annamaria
Altomare, Cosimo Damiano
Liantonio, Antonella
PHARMACOLOGICAL RESEARCH, 2024, 199

← 1 2 3 4 5 →